MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.07
-0.19
-3.61%
Closed 16:00 11/15 EST
OPEN
5.34
PREV CLOSE
5.26
HIGH
5.34
LOW
5.06
VOLUME
54.08K
TURNOVER
--
52 WEEK HIGH
9.76
52 WEEK LOW
3.600
MARKET CAP
59.81M
P/E (TTM)
-1.7534
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CATB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CATB News

  • Solid Bio down 59% premarket on another clinical hold on DMD gene therapy
  • Seeking Alpha - Article.5d ago
  • Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/08 05:27
  • Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/07 18:48
  • Catabasis Pharmaceuticals EPS beats by $0.08
  • seekingalpha.11/07 18:06

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About CATB

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
More

Webull offers Catabasis Pharmaceuticals Inc (CATB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.